<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/Newsletter/style.css"/>
<title>Ensoma Announces $53 Million Financing to Support Key Clinical Milestones for EN-374 and Continued Development of In Vivo Hematopoietic Stem Cell Engineering Pipeline — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/Newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Ensoma Announces $53 Million Financing to Support Key Clinical Milestones for EN-374 and Continued Development of In Vivo Hematopoietic Stem Cell Engineering Pipeline</h2>
    <div class="badge">2025-09-22T11:00:00+00:00</div>
    <ul>
      <li>Company’s Phase 1/2 Clinical Trial of EN-374 in X-linked Chronic Granulomatous Disease is Now Open for Patient Enrollment BOSTON, September 22, 2025 --( BUSINESS WIRE )--Ensoma, an in vivo hematopoietic stem cell (HSC) engineering company with a mission to advance the future of medicine through one-time therapies, today announced the closing of a $53 million financing from its existing syndicate of top-tier investors.</li>
<li>X-linked CGD (X-CGD), the most common form of the condition, comprises 60-70% of cases and is caused by CYBB gene mutations that prevent white blood cells called neutrophils from fighting infection.</li>
<li>The trial is designed to evaluate the safety and potential efficacy of EN-374.</li>
<li>The $53 million financing reflects growing interest in our platform’s potential to address serious diseases through one-time, outpatient treatments,&quot; said Jim Burns, CEO of Ensoma.</li>
<li>Ensoma is currently recruiting participants for a Phase 1/2 open-label, single-ascending-dose study of EN-374 in patients with X-CGD.</li>
<li>View source version on businesswire.com: https://www.businesswire.com/news/home/20250922010282/en/ Contacts Josie Butler, 1AB josie@1abmedia.com</li>
<li>In preclinical studies in animals, EN-374 demonstrated the restoration of CYBB protein expression and NADPH oxidase activity in circulating neutrophils.</li>
    </ul>
    <p>
      <a class="btn" href="https://x.com/intent/tweet?text=Ensoma%20Announces%20%2453%20Million%20Financing%20to%20Support%20Key%20Clinical%20Milestones%20for%20EN-374%20and%20Continued%20Development%20of%20In%20Vivo%20Hematopoietic%20Stem%20Cell%20Engineering%20Pipeline%0A%E2%80%A2%20Company%E2%80%99s%20Phase%201%2F2%20Clinical%20Trial%20of%20EN-374%20in%20X-linked%20Chronic%20Granulomatous%20Disease%20is%20Now%20Open%20for%20Patient%20Enrollment%20BOSTON%2C%20September%2022%2C%202025%20--%28%20BUSINESS%20WIRE%20%29--Ensoma%2C%20an%20in%20vivo%20hematopoietic%20stem%20cell%20%28HSC%29%20engineering%20company%20with%20a%20mission%20to%20advance%20the%20future%20of%20medicine%20through%20one-time%20therapies%2C%20today%20announced%20the%20closing%20of%20a%20%2453%20million%20financing%20from%20its%20existing%20syndicate%20of%20top-tier%20investors.%0A%E2%80%A2%20X-linked%20CGD%20%28X-CGD%29%2C%20the%20most%20common%20form%20of%20the%20condition%2C%20comprises%2060-70%25%20of%20cases%20and%20is%20caused%20by%20CYBB%20gene%20mutations%20that%20prevent%20white%20blood%20cells%20called%20neutrophils%20from%20fighting%20infection.%0A%E2%80%A2%20The%20trial%20is%20designed%20to%20evaluate%20the%20safety%20and%20potential%20efficacy%20of%20EN-374.%0A%E2%80%A2%20The%20%2453%20million%20financing%20reflects%20growing%20interest%20in%20our%20platform%E2%80%99s%20potential%20to%20address%20serious%20diseases%20through%20one-time%2C%20outpatient%20treatments%2C%22%20said%20Jim%20Burns%2C%20CEO%20of%20Ensoma.%0A%E2%80%A2%20Ensoma%20is%20currently%20recruiting%20participants%20for%20a%20Phase%201%2F2%20open-label%2C%20single-ascending-dose%20study%20of%20EN-374%20in%20patients%20with%20X-CGD.%0A%E2%80%A2%20View%20source%20version%20on%20businesswire.com%3A%20https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20250922010282%2Fen%2F%20Contacts%20Josie%20Butler%2C%201AB%20josie%401abmedia.com%0A%E2%80%A2%20In%20preclinical%20studies%20in%20animals%2C%20EN-374%20demonstrated%20the%20restoration%20of%20CYBB%20protein%20expression%20and%20NADPH%20oxidase%20activity%20in%20circulating%20neutrophils.&url=https%3A%2F%2Fsuavir600.github.io%2FNewsletter%2Farticles%2Fensoma-announces-53-million-financing-to-support-key-clinical-milestones-for-en%2F" target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a class="btn" href="https://finance.yahoo.com/news/ensoma-announces-53-million-financing-110000330.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>